| 11/16/2026 7:29 PM | ADAR1 Capital Management, LLC (1940272) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G/A | |
| 11/16/2026 6:16 PM | Cyclerion Therapeutics (1755237) Subject TCG Crossover GP II, LLC (1969280) Filed by | Form SCHEDULE 13G | |
| 11/16/2026 12:16 PM | Janus Henderson Group Ltd. (1274173) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G | |
| 11/16/2026 10:52 AM | Cyclerion Therapeutics (1755237) Subject WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by | Form SCHEDULE 13G | |
| 11/16/2026 5:05 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G/A | |
| 11/10/2026 9:03 AM | JPMORGAN CHASE & CO (19617) Filed by JPMORGAN CHASE & CO (19617) Filed by JPMORGAN CHASE & CO (19617) Filed by JPMORGAN CHASE & CO (19617) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G | |
| 11/09/2026 3:45 PM | Cyclerion Therapeutics (1755237) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 11/05/2026 7:00 AM | Cyclerion Therapeutics (1755237) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/05/2026 6:05 AM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/22/2026 3:06 PM | Higgins Michael J (1478521) Reporting Cyclerion Therapeutics (1755237) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/15/2026 3:30 PM | J. WOOD CAPITAL ADVISORS LLC (1586446) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G/A | |
Get the Latest News and Ratings for KRSA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 10/15/2026 3:15 PM | Cyclerion Therapeutics (1755237) Filer | Form DEF 14A | |
| 10/07/2026 10:47 AM | FMR LLC (315066) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G/A | |
| 10/05/2026 3:14 PM | Cyclerion Therapeutics (1755237) Filer | Form PRE 14A | |
| 09/23/2026 3:50 PM | DESOUZA ERROL B (1213895) Reporting Cyclerion Therapeutics (1755237) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/22/2026 3:56 PM | DESOUZA ERROL B (1213895) Reporting Cyclerion Therapeutics (1755237) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/18/2026 6:20 PM | GENERAL ATLANTIC, L.P. (1017645) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G | |
| 09/18/2026 3:49 PM | DESOUZA ERROL B (1213895) Reporting Cyclerion Therapeutics (1755237) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/16/2026 6:55 AM | Cyclerion Therapeutics (1755237) Subject Wellington Biomedical Innovation Master Investors (0) Cayman | Form SCHEDULE 13G | |
| 09/15/2026 3:56 PM | Cyclerion Therapeutics (1755237) Subject Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by | Form SCHEDULE 13D | |
| 09/11/2026 4:25 PM | Fairmount Funds Management LLC (1802528) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13D | |
| 09/11/2026 3:25 PM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/10/2026 4:43 PM | Gottesdiener Andrew (1972292) Reporting Cyclerion Therapeutics (1755237) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/10/2026 4:44 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Co-Invest VI L.P. (2124208) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Harwin Peter Evan (1663607) Reporting Kiselak Tomas (1830177) Reporting Cyclerion Therapeutics (1755237) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/10/2026 4:45 PM | Cyclerion Therapeutics (1755237) Issuer Shah Nimish P (1698082) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/10/2026 4:45 PM | Cyclerion Therapeutics (1755237) Issuer Pernice Michelle Patricia (2126413) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/10/2026 4:26 PM | Cyclerion Therapeutics (1755237) Issuer Vignola Mark J. (1775429) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:29 PM | Cyclerion Therapeutics (1755237) Issuer Shah Nimish P (1698082) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:30 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Co-Invest VI L.P. (2124208) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Harwin Peter Evan (1663607) Reporting Kiselak Tomas (1830177) Reporting Cyclerion Therapeutics (1755237) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:31 PM | Gottesdiener Andrew (1972292) Reporting Cyclerion Therapeutics (1755237) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:34 PM | HENSON HEIDI (1283301) Reporting Cyclerion Therapeutics (1755237) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:34 PM | Cyclerion Therapeutics (1755237) Issuer Pernice Michelle Patricia (2126413) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:36 PM | Cyclerion Therapeutics (1755237) Issuer Leoni Matthew James (2150640) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 09/10/2026 4:36 PM | Cyclerion Therapeutics (1755237) Issuer Violin Jonathan (1730615) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 08/27/2026 5:01 AM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/25/2026 3:15 PM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/25/2026 3:17 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 08/18/2026 4:27 PM | CHICKO RHONDA M. (1740376) Reporting Cyclerion Therapeutics (1755237) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/18/2026 4:21 PM | Cyclerion Therapeutics (1755237) Issuer Graul Regina Margaret (2002981) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 8:29 PM | ADAR1 Capital Management, LLC (1940272) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G | |
| 08/14/2026 5:02 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Cyclerion Therapeutics (1755237) Subject | Form SCHEDULE 13G | |
Your free book is about to disappear (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link.
He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes |
| 08/12/2026 3:33 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 08/10/2026 3:52 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 08/06/2026 4:22 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 08/04/2026 3:15 PM | Cyclerion Therapeutics (1755237) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/03/2026 4:01 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 07/22/2026 4:14 PM | Cyclerion Therapeutics (1755237) Filer | Form S-4/A | |
| 07/20/2026 6:50 PM | Cyclerion Therapeutics (1755237) Subject Hecht Peter M (1478485) Filed by | Form SCHEDULE 13D/A | |
| 07/20/2026 4:04 PM | Cyclerion Therapeutics (1755237) Issuer Hecht Peter M (1478485) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/10/2026 4:30 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 05/07/2026 9:42 AM | Cyclerion Therapeutics (1755237) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 04/30/2026 7:30 AM | Cyclerion Therapeutics (1755237) Filer | Form 10-K/A | |
| 04/17/2026 8:46 PM | Cyclerion Therapeutics (1755237) Filer | Form S-4 Registration statement under Securities Act of 1933 | |
| 04/01/2026 3:25 PM | Cyclerion Therapeutics (1755237) Subject | Form 425 | |
| 02/17/2026 6:21 AM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 7:33 AM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/01/2025 4:13 PM | Cyclerion Therapeutics (1755237) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |